Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 12/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 8/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390094 | 1.00 | POLB (0.48) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL27060755 | 0.87 | HTR2C (0.51) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL8195609 | 0.84 | HTR2C (0.34) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL21657103 | 0.83 | HTR2C (0.45) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL20792776 | 0.80 | POLB (0.43) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL15880652 | 0.80 | POLB (0.45) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL22999621 | 0.78 | CDK5 (0.51) | POLBSMN1; SMN2CDK2CDK4CDK6 | |
| SCHEMBL9959904 | 0.78 | CDK2 (0.67) | SMN1; SMN2HTR2CCDK2CDK4CDK6 | |
| SCHEMBL4135011 | 0.77 | POLB (0.51) | POLBSMN1; SMN2HTR2CCDK2CDK4 | |
| SCHEMBL2183634 | 0.77 | POLB (0.51) | POLBSMN1; SMN2HTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9296747-B1 | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | POLB 2065/4885SMN1; SMN2 2503/4885HTR2C 3163/4885 |
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | KDR, PTGFR, TEK | POLB 3010/4885SMN1; SMN2 1769/4885HTR2C 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.